Introducing New Biosimilars Into Current Treatment Algorithms
Three biosimilar products are now licensed for the treatment of rheumatic diseases in Europe. The European Medicines Agency (EMA) requires that similarity between a biosimilar and its reference product is demonstrated using a rigorous, stepwise process that includes extensive physicochemical and bio...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2016-07-01
|
| Series: | European Medical Journal Rheumatology |
| Subjects: | |
| Online Access: | http://emjreviews.com/wp-content/uploads/Introducing-New-Biosimilars-Into-Current-Treatment-Algorithms.pdf |